Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Updates

 Cadila Healthcare Ltd has informed BSE that the Company's Oral Solid Dosage drug manufacturing plant located at SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in January 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised. It may be mentioned that this plant is a separate manufacturing unit and does not form a part of the Moraiya formulations manufacturing facility.
02-09-2016
Bigul

Now, Roche takes Zydus Cadila to court over breast cancer drug

 The petition states the approval of Cadila's drug as a biosimilar has caused Roche irreparable damage in violation of applicable law for testing and approval of biosimilar drugs.
18-08-2016

Cadila gets EIR from USFDA for Changodar topical facility

 Receipt of the EIR indicates that the USFDA has closed the inspection, as the company has addressed observations related to good manufacturing practices raised
16-08-2016
Bigul

Updates

 Cadila Healthcare Ltd has informed BSE that the Company's Topical manufacturing facility located at Changodar, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in March 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised. The topical plant is a dedicated facility for manufacturing ointments and does not form a part of the Moraiya formulations manufacturing plant.
16-08-2016

Cadila acquires skin treatment lotion Melgain from Issar Pharma

 Melgain will be marketed in India by Liva Healthcare, a specialty division of Zydus group catering to the dermatological segment
09-08-2016
Bigul

Zydus strengthens its derma portfolio with the brand acquisition of MELGAIN from Issar Pharma in India

 Cadila Healthcare Ltd has informed BSE regarding a Press Release dated August 08, 2016 titled "Zydus strengthens its derma portfolio with the brand acquisition of MELGAIN from Issar Pharma in India."
08-08-2016
Bigul

Buy Cadila Healthcare Ltd., target Rs 440.0 : Citigroup

 Citigroup sees limited scope for further deterioration in Cadilla Healthcare financials.
05-08-2016
Bigul

Updates

 On June 20, 2016, the Company had announced the acquisition of two ANDAs from Teva that were being divested by Teva as a pre-condition to its acquisition of Allergan's generic business. The acquisition of these ANDAs was contingent on the closing of the Teva-Allergan Generics transaction and approval by the US Federal Trade Commission.Cadila Healthcare Ltd has now informed BSE that the transaction has now been completed and these ANDAs have...
05-08-2016
Bigul

Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

 Cadila Healthcare Ltd has informed BSE regarding the details of Voting results at the 21st Annual General Meeting (AGM) of the Company held on August 03, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizer's Report.
05-08-2016
Bigul

Outcome of AGM

 Cadila Healthcare Ltd has informed BSE that the 21st Annual General Meeting (AGM) of the Company was held on August 03, 2016.
04-08-2016
Next Page
Close

Let's Open Free Demat Account